Olav Bergheim, Chairman
Olav is the Founder and Managing Director of Fjord Ventures LLC, a life sciences accelerator company whose portfolio includes Adagio Medical, Inc.; Allegro Medical, Inc.; Anaxiom Corporation; Kato Pharmaceuticals, Inc.; Metronom Health, Inc.; Prelude Corporation; Sonendo, Inc.; Volante Diagnostics, Inc.; and YAP Therapeutics, Inc. Each of these companies was founded by Olav. Previously, Olav was General Partner of Domain Associates, where he started VenPro; 3F Therapeutics (acquired by Medtronic); Vessix Vascular (acquired by Boston Scientific); Volcano Therapeutics (acquired by Phillips); and Glaukos Corporation. Earlier, Olav spent 18 years in general management positions at Baxter Healthcare Corporations.
Terrance McGovern, Co-Founder and Chief Executive Officer
Terry is a senior healthcare venture capital and corporate executive with broad expertise in biotechnology, pharmaceuticals, medical devices and diagnostics. Focused on early-stage novel technologies with strategic partnering opportunities. Primary responsibility for over 100 successful mergers and acquisitions, public and private financings and biotech venture investments with companies based in North America Europe and Asia. Held senior management positions of large corporate departments including CIBC and the Bank of Montreal as well as early-stage companies including CEO and CFO as well as Board of Director Positions. He holds a BS in Biology from Georgetown University an MS in Mammalian Physiology from Rutgers University and an MBA from the Wharton School.
Andrew Wade CPA, CFO
Andy brings nearly 20 years of broad corporate finance and accounting experience, including nearly 15 years within the medical device industry. Most recently, Andy was Senior Director Finance and Corporate Controller at Lombard Medical, a publicly-traded medical device company. In addition, Andy has held management positions with a number of life science firms, including Fjord Ventures, Alsius Corporation and Cardiac Science. Andy began his career with KPMG and holds a B.A. in Business Economics with an emphasis in Accounting from the University of California at Santa Barbara.
Jeda Voska, Sr. Mgr. Research & Development
Jeda is a biopharmaceutical scientist and engineer (MS) with 10+ years in pharmaceutical and medical devices. She developed the complex process to successfully manufacture Kato’s patented extended-release technology and ResolvER™ drug product. Ms. Voska has supported pharmaceutical and medical device innovation, GMP manufacturing and commercialization of products. Ms. Voska has a degree in Chemistry from the University of California, Santa Barbara (UCSB) and a Masters in Chemical Engineering from the University of Southern California (USC).
Maria Rosadel ‘Madel’ Dionisio, Senior Regulatory and Clinical Engineer
Madel has extensive experience in regulatory affairs, clinical research, drug development and manufacturing. She has supported multiple early-phase clinical trials for new diabetes drugs and devices, including continuous glucose monitoring devices, insulin pumps, and artificial pancreas systems. Ms. Dionisio is also a trained chemist with a strong background in GMP manufacturing of drug substances for clinical research and commercial use. She holds a BS in Chemistry with an emphasis in Clinical Biochemistry from the University of the Philippines, Diliman.
Kenneth Mandell, MD, Ph.D.
Dr. Mandell is the Founder and CEO of LayerBio and an expert in the field of ocular drug delivery. A Harvard-trained ophthalmologist and serial entrepreneur, he previously served as CMO at Neurotech Pharmaceuticals and Noveome Biotherapeutics, and prior to that he was Acting VP of Medical Affairs at Aldeyra Therapeutics. He is currently a strategic advisor to Kato Pharmaceuticals, Regenerate Therapeutics, and Aramis Biosciences. He previously served as a consultant to Eloxx Pharmaceuticals, Aciex Therapeutics, Clearside Biomedical, and Envisia Therapeutics. He is currently the medical monitor for more than a dozen studies at the National Eye Institute.
Charles Wyckoff, MD, Ph.D.
Dr. Charles C. Wykoff is a board-certified Medical and Surgical Retina Specialist and ophthalmologist with Retina Consultants of Texas (RCTX). Leading a top international research facility for vitreoretinal diseases, Dr. Wykoff serves as Director of Research at RCTX and the Greater Houston Retina Research Foundation (GHRRF), and Chairman of the Research and Clinical Trials Subcommittee, Retina Consultants of America. In addition, he serves as the elected Deputy Chair of Ophthalmology for the Blanton Eye Institute, Houston Methodist Hospital. Dr. Wykoff has been awarded the American Academy of Ophthalmology Secretariat and Achievement Awards as well as the American Society of Retina Specialists Senior Honor and Young Investigator Awards
Arshad Khanani, M.D.
Dr. Khanani is Managing Partner, Director of Clinical Research at Sierra Eye Associates. and Clinical Associate Professor at the University of Nevada, Reno.Dr. Khanani is a fellowship-trained vitreoretinal specialist and is certified by The American Board of Ophthalmology. He graduated magna cum laude in chemistry from Washington University in St. Louis with a Bachelors's and Masters's degree. While at Washington University, Dr. Khanani was honored with The Howard Hughes Medical Institute Research Award.
Roger Goldberg, M.D. , M.B.A.
Dr. Goldberg is a member of Bay Area Retina Associates based in Walnut Creek CA. He graduated from both college and medical school at Yale University. He completed his residency in Miami at the Bascom Palmer Eye Institute, He returned to Boston for a fellowship in Vitreoretinal Diseases and Surgery at Tufts and Ophthalmic Consultants of Boston. Dr. Goldberg is board certified by the American Board of Ophthalmology and is an active member of the American Society of Retinal Specialists, the Retina Society, and the American Academy of Ophthalmology.
James Bernstein, Ph.D. Quality and CMC Advisor
Founder and lead consultant of Live Oak Pharmaceutical Consulting (established 2007). 30+ years in Pharmaceutical development at GlaxoSmithKline and analytical development at GlaxoWellcome. Lead 15+ CMC projects to fruition supporting both drug substance and drug product.
Stephen Montgomery, Ph.D., Toxicology and Regulatory Advisor
40+ years of toxicology expertise in pharmaceuticals, medical devices, food additives, dietary supplements, and nutraceutical products. Responsibilities ranging from pre-clinical safety assessments and toxicology for new drugs with the FDA through Senior Director positions supporting the pre-clinical and regulatory strategy and evaluations for FDA IND/NDA submissions and new product acquisitions.
Angela Kothe, OD, Ph.D., Regulatory Affairs Advisor
28 years of experience in pharmaceutical clinical and regulatory affairs. Served as Senior Director, Regulatory Affairs at Alcon before founding Silver Pharma Consulting in 2012, specializing in Clinical and Regulatory affairs.
Thomas Hohman, Scientific Advisor
Founder of Envision Consulting. Tom has 30 years of experience in ophthalmology drug and clinical development in senior executive roles including Vice President of Retina Discovery and Translation medicine at Allergan. Prior to that, he held senior R&D positions at Alcon, Novartis, and Pfizer.
Alan Weiner, Ph.D., CMC Advisor
Founder of DrugDel Consulting, LLC. He has 40 years of experience in ophthalmic formulation, liposome development, and drug delivery. Founding scientist at The Liposome Company, VP R&D Escalon Ophthalmics, and Sr. Director of Development, Alcon.